These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

606 related articles for article (PubMed ID: 31276927)

  • 1. Incidence of pediatric neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease in Denmark 2008‒2018: A nationwide, population-based cohort study.
    Boesen MS; Jensen PEH; Born AP; Magyari M; Nilsson AC; Hoei-Hansen C; Blinkenberg M; Sellebjerg F
    Mult Scler Relat Disord; 2019 Aug; 33():162-167. PubMed ID: 31276927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study.
    Takai Y; Misu T; Kaneko K; Chihara N; Narikawa K; Tsuchida S; Nishida H; Komori T; Seki M; Komatsu T; Nakamagoe K; Ikeda T; Yoshida M; Takahashi T; Ono H; Nishiyama S; Kuroda H; Nakashima I; Suzuki H; Bradl M; Lassmann H; Fujihara K; Aoki M;
    Brain; 2020 May; 143(5):1431-1446. PubMed ID: 32412053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes.
    Duignan S; Wright S; Rossor T; Cazabon J; Gilmour K; Ciccarelli O; Wassmer E; Lim M; Hemingway C; Hacohen Y
    Dev Med Child Neurol; 2018 Sep; 60(9):958-962. PubMed ID: 29468668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.
    Rostásy K; Mader S; Hennes EM; Schanda K; Gredler V; Guenther A; Blaschek A; Korenke C; Pritsch M; Pohl D; Maier O; Kuchukhidze G; Brunner-Krainz M; Berger T; Reindl M
    Mult Scler; 2013 Jul; 19(8):1052-9. PubMed ID: 23257621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
    Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
    J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype.
    Kitley J; Woodhall M; Waters P; Leite MI; Devenney E; Craig J; Palace J; Vincent A
    Neurology; 2012 Sep; 79(12):1273-7. PubMed ID: 22914827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis.
    Fan S; Xu Y; Ren H; Guan H; Feng F; Gao X; Ding D; Fang F; Shan G; Guan T; Zhang Y; Dai Y; Yao M; Peng B; Zhu Y; Cui L
    Mult Scler Relat Disord; 2018 Feb; 20():144-152. PubMed ID: 29414288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
    Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
    JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder.
    Narayan R; Simpson A; Fritsche K; Salama S; Pardo S; Mealy M; Paul F; Levy M
    Mult Scler Relat Disord; 2018 Oct; 25():66-72. PubMed ID: 30048919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic algorithm for relapsing acquired demyelinating syndromes in children.
    Hacohen Y; Mankad K; Chong WK; Barkhof F; Vincent A; Lim M; Wassmer E; Ciccarelli O; Hemingway C
    Neurology; 2017 Jul; 89(3):269-278. PubMed ID: 28615429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MOG antibody-related disorders: common features and uncommon presentations.
    Cobo-Calvo Á; Ruiz A; D'Indy H; Poulat AL; Carneiro M; Philippe N; Durand-Dubief F; Deiva K; Vukusic S; Desportes V; Marignier R
    J Neurol; 2017 Sep; 264(9):1945-1955. PubMed ID: 28770374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.
    Mader S; Gredler V; Schanda K; Rostasy K; Dujmovic I; Pfaller K; Lutterotti A; Jarius S; Di Pauli F; Kuenz B; Ehling R; Hegen H; Deisenhammer F; Aboul-Enein F; Storch MK; Koson P; Drulovic J; Kristoferitsch W; Berger T; Reindl M
    J Neuroinflammation; 2011 Dec; 8():184. PubMed ID: 22204662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MRI findings in pediatric neuromyelitis optica spectrum disorder with MOG antibody: Four cases and review of the literature.
    Ikeda A; Watanabe Y; Kaba H; Kaneko K; Takahashi T; Takeshita S
    Brain Dev; 2019 Apr; 41(4):367-372. PubMed ID: 30447856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
    Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
    Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Analysis of T-Cell Responses to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein in Inflammatory Demyelinating Central Nervous System Diseases.
    Hofer LS; Ramberger M; Gredler V; Pescoller AS; Rostásy K; Sospedra M; Hegen H; Berger T; Lutterotti A; Reindl M
    Front Immunol; 2020; 11():1188. PubMed ID: 32625206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome.
    Hennes EM; Baumann M; Schanda K; Anlar B; Bajer-Kornek B; Blaschek A; Brantner-Inthaler S; Diepold K; Eisenkölbl A; Gotwald T; Kuchukhidze G; Gruber-Sedlmayr U; Häusler M; Höftberger R; Karenfort M; Klein A; Koch J; Kraus V; Lechner C; Leiz S; Leypoldt F; Mader S; Marquard K; Poggenburg I; Pohl D; Pritsch M; Raucherzauner M; Schimmel M; Thiels C; Tibussek D; Vieker S; Zeches C; Berger T; Reindl M; Rostásy K;
    Neurology; 2017 Aug; 89(9):900-908. PubMed ID: 28768844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of clinical characteristics and prognoses in patients with different AQP4-Ab and MOG-Ab serostatus with neuromyelitis optica spectrum disorders.
    Du Q; Shi Z; Chen H; Zhang Y; Wang J; Qiu Y; Zhao Z; Zhang Q; Zhou H
    J Neuroimmunol; 2021 Apr; 353():577494. PubMed ID: 33515897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and MRI phenotype of children with MOG antibodies.
    Fernandez-Carbonell C; Vargas-Lowy D; Musallam A; Healy B; McLaughlin K; Wucherpfennig KW; Chitnis T
    Mult Scler; 2016 Feb; 22(2):174-84. PubMed ID: 26041801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective analysis of children with myelin oligodendrocyte glycoprotein antibody-related disorders.
    Konuskan B; Yildirim M; Gocmen R; Okur TD; Polat I; Kilic H; Saltik S; Ozturk Z; Gucuyener K; Altunbasak S; Celik T; Kose G; Yilmaz A; Komur M; Kayilioglu H; Anlar B
    Mult Scler Relat Disord; 2018 Nov; 26():1-7. PubMed ID: 30212767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.